PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo

Human Gene Therapy

Volumn 10, Issue 8, 1999, Pages 1349-1358

  O'Riordan, Catherine R ^a   Lachapelle, Amy ^a   Delgado, Cristina ^b   Parkes, Vincent ^b   Wadsworth, Samuel C ^a   Smith, Alan E ^a   Francis, Gillian E ^b  

^a GENZYME CORPORATION   (United States)

^b PolyMASC Pharmaceuticals plc   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL; MACROGOL DERIVATIVE; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; VIRUS VECTOR;

ADENOVIRUS; ARTICLE; CELL SURFACE; CONTROLLED STUDY; NONHUMAN; VIRUS CAPSID; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION;

ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, VIRAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MICE; NEUTRALIZATION TESTS; POLYETHYLENE GLYCOLS; SULFONES; VIRION;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MIRIDAE;

EID: 0033587174     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018021     Document Type: Article

References (38)

1. ABUCHOWSKI, A., MCCOY, J.R., PALCZUK, N.C., VAN ES, T., and DAVIS, F.F. (1977). Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252, 3582-3586.
2. ABUCHOWSKI, A., KAZSO, G.M., VERHOEST, C.R., JR., VAN ES, T., KAFKEWITZ, D., NUCCI, M.L., VIAU, A.T., and DAVIS, F.F. (1984). Cancer therapy with chemically modified enzymes. Antitumour properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys. 7, 175-186.
3. CHILLON, M., LEE, J.H., FASSENDER, A., and WELSH, M.J. (1998). Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. Gene Ther. 5, 995-1002.
4. DAI, Y., SCHWARZ, E.M., GU, D., ZHANG, W., SARVETNICK, N., and VERMA, I.M. (1995). Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long term expression. Proc. Natl. Acad. Sci. U.S.A. 92, 1401-1405.
5. DELGADO, C., PATEL, J.N., FRANCIS, G.E., and FISHER, D. (1990). Coupling of polyethylene glycol to albumin under very mild conditions by activation with tresyl chloride characterisation of the conjugate by partitioning in aqueous two-phase systems. Biotechnol. Appl. Biochem. 12, 119-128.
6. DELGADO, C., FRANCIS, G.E., and FISHER, D. (1992). Uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 9, 249-304.
7. ENGELHARDT, J.F., YE, X., DORANZ, B., and WILSON, J.M. (1994). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory responses in mouse liver. Proc. Natl. Acad. Sci. U.S.A. 91, 6196-6200.
8. FASBENDER, A., ZABNER, J., CHILLON, M., MONINGER, T.O., PUGA, A.P., DAVIDSON, B.L., and WELSH, M.J. (1997). Complexes of adenovirus with polycationic polymers and cationic lipids increase the efficiency of gene transfer in vitro and in vivo. J. Biol. Chem. 272, 6479-6489.
9. FRANCIS, G.E., DELGADO, C., and FISHER, D. (1991). PEG-modified proteins. In Stability of Protein Pharmaceutical: In Vivo Pathways of Degradation and Strategies for Protein Stabilisation, Vol. 3: Pharmaceutical Biotechnology. T.J. Ahern and M. Manning, eds. (Plenum, New York) pp. 235-263.
10. FRANCIS, G.E., DELGADO, C., FISHER, D., MALIK, F., and AGRAWAL, A.K. (1996). Polyethylene glyeol modification: Relevance of improved methodology to tumour targeting. J. Drug Target. 3, 321-340.
11. FRANCIS, G.E., FISHER, D., DELGADO, C., MALIK, F., GARDINER, A., and NEALE, D. (1998). PEGylation of cytokines and other therapeutic proteins and peptides: The importance of biological optimisation of coupling techniques. Int. J. Hematol. 68, 1-18.
12. GAHERY-SEGARD, H., JUILLARD, V., GASTON, J., LENGAGNE, R., PAVIRANI, A., BOULANGER, P., and GUILLET, J.-G. (1997). Humoral immune response to the capsid components of recombinant adenoviruses: Routes of immunization modulate virus-induced Ig subclass shifts. Eur. J. Immunol. 27, 653-659.
13. GAHERY-SEGARD, H., FARACE, F., GODFRIN, D., GASTON, J., LENGAGNE, R., TURSZ, T., BOULANGER, P., and GUILLET, J.-G. (1998). Immune responses to recombinant capsid proteins of adenovirus in human: Antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72, 2388-2397.
14. ISHIBASHI, S., BROWN, M.S., GOLDSTEIN, J.L., GERARD, R.D., HAMMER, R.E., and HERZ, J. (1993). Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92, 883-893.
15. KAPLAN, J.M., ST. GEORGE, J.A., PENNINGTON, S.E., KEYES, L.D., JOHNSON, R.P., WADSWORTH, S.C., and SMITH, A.E. (1996). Humoral and cellular immune responses of non-human primates to long term repeated lung exposure. Gene Ther. 3, 117-127.
16. KAPLAN, J.M., PENNINGTON, S.E., ST. GEORGE, J.A., WOODWORTH, L.A., FASBENDER, A., MARSHALL, J., CHENG, S.H., WADSWORTH, S.C., GREGORY, R.J., and SMITH, A.E. (1998). Potentiation of gene transfer to the mouse lung by complexes of adenovirus vector and polycations improves therapeutic potential. Hum. Gene Ther. 9, 1469-1479.
17. KAY, M., LANDEN, C.N., ROTHENBERG, S.R., TAYLOR, L.A., LELAND, F., WIEHLE, S., FANG, B., BELLINGER, D., FINEGOLD, M., THOMPSON, A.R., READ, M., BRINKHOUS, K.M., and WOO, S.L.C. (1994). In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc. Natl. Acad. Sci. U.S.A. 91, 2353-2357.
18. MASTRANGELI, A., HARVEY, B.-G., YAO, J., WOLFF, G., KOVESDI, I., CRYSTAL, R.G., and FALCK-PEDERSON, E. (1996). "Sero-switch" adenovirus-mediated in vivo gene transfer: Circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 7, 79-87.
19. MOLNAR-KIMBER, K.L., STERMAN, D.H., CHANG, M., ELBASH, M., ELSHAMI, A., GELFAND, K., KANG, E., WILSON, J.M., KAISER, L.R., and ALBELDA, S.M. (1998). Impact of preexisting and induced humoral and cellular immune responses in an adenoviral based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 9, 2121-2133.
20. PRAGE, L., PETERSSON, U., HOGLUND, S., LONBERG-HOLM, K., and PHILIPSON, L. (1970). Structural proteins of adenoviruses. J. Virol. 42, 341-358.
21. QUINN, B., PERRICAUDET, L.D., TAJBAKHSH, S., and MANDEL, J.L. (1992). Adenovirus as an expression vector in muscle cells in vivo. Proc. Natl. Acad. Sci. U.S.A. 89, 2581-2584.
22. RICH, D.P., COUTURE, L.A., CARDOZA, L.M., GUIGGO, V.M., ARMENTANO, D., ESPINO, P.C., HEHIR, K., WELSH, M.J., SMITH, A.E., and GREGORY, R. (1993). Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum. Gene Ther. 4, 461-476.
23. RICHTER, A.W., and AKERBLOM, E. (1983). Antibodies against polyethylene glycol produced in animals by immunization with monomethoxypolyethylene glycol modified proteins. Int. Arch. Allergy Appl. Immunol. 70, 124-131.
24. ROSENFELD, M.A., YOSHIMURA, K., TRAPNELL, B.C., YONEYAMA, K., ROSENTHAL, E.R., DALEMANS, W., FUKAYAMA, M., BARGON, J., STIER, L.E., STRATFORD-PERRICAUDET, L., PERRICAUDET, M., GUGGINO, W.B., PAVIRANI, A., LECOQ, J.P., and CRYSTAL, R.G. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143-155.
25. SCARIA, A., ST. GEORGE, J.A., GREGORY, R.J., NOELLE, R.J., WADSWORTH, S.C., SMITH, A.E., and KAPLAN, J.M. (1997). Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Ther. 4, 611-617.
26. SCARIA, A., ST. GEORGE, J.A., JIANG, C., KAPLAN, J.M., WADSWORTH, S.C., and GREGORY, R.J. (1998). Adenovirus-mediated persistent cystic fibrosis transmembrane conductance regulator expression in mouse airway epithelium. J. Virol. 72, 7302-7309.
27. SIMON, R.H., ENGELHARDT, J.F., YANG, Y., ZEPEDA, M., WEBER-PENDLETON, S., GROSSMAN, M., and WILSON, J.M. (1993). Adenovirus mediated transfer of the CFTR gene to lung of non-human primates: Toxicity study. Hum. Gene Ther. 4, 771-780.
28. SMITH, T.A.G., MEHAFFEY, M.G., KAYDA, D.B., SAUNDERS, J.M., YEI, S., TRAPNELL, B.C., MCCLELLAND, A., and KALEKO, M. (1993). Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Gene Ther. 5, 397-402.
29. TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., and LEIDEN, J.M. (1996). Immune responses to transgene encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus. Nature Med. 2, 545-550.
30. VAN GINKEL, F.W., LIU, C., SIMECKA, J.W., DONG, J.Y., GREENWAY, T., FRIZZELL, R.A., KIYONO, H., MCGHEE, J.R., and PASCUAL, D.W. (1995). Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Hum. Gene Ther. 6, 895-903.
31. VAN OOSTRUM, J., and BURNETT, R.M. (1985). Molecular composition of the adenovirus type 2 virion. J. Virol. 56, 439-448.
32. WILSON, C.B., EMBREE, L.J., SCHOWALTER, D., ALBERT, R., ARUFFO, A., HOLLENBAUGH, D., LINSLEY, P., and KAY, M.A. (1998). Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration. J. Virol. 72, 7542-7550.
33. WOHLFART, C. (1988). Neutralization of adenoviruses: Kinetics, stoichiometry, and mechanisms. J. Virol. 62, 2321-2328.
34. YANG, Y., NUNES, F.A., BERENSCI, K., GONCZOL, E., ENGELHARDT, J.F., and WILSON, J.M. (1994). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nature Genet. 7, 362-369.
35. YANG, Y., LI, Q., ERTL, H.C.J., and WILSON, J.M. (1995a). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
36. YANG, Y., TRINCHIERI, G., and WILSON, J.M. (1995b). Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med. 1, 890-893.
37. YANG, Y., JOOSS, K.U., SU, Q., ERTL, H.C., and WILSON, J.M. (1996). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3, 137-144.
38. YEI, S., MITTEREDER, N., TANG, K., O'SULLIVAN, C., and TRAPNELL, B.C. (1994). Adenovirus mediated gene transfer for cystic fibrosis: Quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther. 1, 192-200.